Post Marketing Surveillance Study To Observe Safety And Efficacy Of Aromasin In The Patients With Early Or Advanced Breast Cancer

• Status: Completed
• Trial end date: 2014-06-01
• Target enrollment: 0
• Participant gender: Female

Summary

This non-interventional study is to monitor use in real practice in Korea including adverse events on Aromasin (Exemestane).

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Exemestane

Criteria

Inclusion Criteria:

• - Postmenopausal women with breast cancer eligible for hormonal therapy.

Exclusion Criteria:

• Pregnant breast-feeding premenopausal.